Skip to content
Clinical Trials – home

Jagiellońskie Centrum Innowacji Sp. z o.o.

Verified siteinfo

Poland Ul. Profesora Michala Bobrzynskiego 14, 30-348 Cracow, Poland

  • 12 trials recruiting
  • Ovarian cancer · Breast cancer · Breast cancer metastatic
  • Adults and children

About Specializations

Jagiellońskie Centrum Innowacji Sp. z o.o. in Cracow, Poland specialises in clinical trials of conditions such as Ovarian cancer, Breast cancer, Breast cancer metastatic, Dermatitis atopic, and other specialisations. This site conducts important research.

Main research areas of the site

Rheumatology and Osteoarthritis

The medical center is at the forefront of rheumatology research, particularly focusing on knee osteoarthritis. The center's studies aim to understand the impact of treatments like naproxen sodium on synovial fluid and inflammatory markers such as Interleukin-6 (IL-6).

  • Synovial fluid analysis
  • Inflammatory cytokine modulation
  • Non-steroidal anti-inflammatory drugs (NSAIDs)

These investigations contribute to improved therapeutic strategies for managing osteoarthritis symptoms and enhancing patient quality of life.

Oncology and Cancer Treatment

Specializing in oncology, the center conducts pivotal research on various cancers, including platinum-sensitive epithelial ovarian cancer and papillary renal cell carcinoma. The focus is on innovative therapies like mirvetuximab soravtansine and savolitinib to improve progression-free survival rates.

  • Targeted cancer therapies
  • Progression-free survival metrics
  • Combination drug regimens

These efforts are crucial in developing personalized treatment plans and advancing cancer care.

Dermatology and Skin Disorders

The center is renowned for its research in dermatology, focusing on conditions like acne vulgaris and prurigo nodularis. Studies explore the efficacy and safety of novel topical treatments, such as N-Acetyl-GED-0507-34-Levo gel and povorcitinib.

  • Topical drug development
  • Long-term safety assessments
  • Itch and lesion management

This research is instrumental in enhancing therapeutic options and improving patient outcomes in dermatological care.

Immunology and Autoimmune Diseases

Focusing on immunology, the center investigates treatments for autoimmune conditions such as plaque psoriasis. Research includes evaluating the efficacy of innovative therapies like JNJ-77242113 to manage moderate to severe cases.

  • Autoimmune disease management
  • Biologic and small molecule therapies
  • Clinical efficacy trials

These studies are pivotal in advancing understanding and treatment of autoimmune disorders.

Gynecologic Oncology

The center excels in gynecologic oncology, with research targeting cervical cancer and high-grade serous ovarian cancer. The focus is on assessing the safety and efficacy of treatments like volrustomig and ZN-c3.

  • Advanced cancer therapies
  • Safety and tolerability studies
  • Antitumor activity evaluation

This research is vital for developing effective treatment protocols and improving survival rates in gynecologic cancers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Profesora Michala Bobrzynskiego 1430-348 CracowPoland
Recruiting now
12 trials
Conditions studied
37
Partner status
Verified site

More sites in CracowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

40 clinical trials

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Pfizer Inc.

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Pfizer Inc.

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Ovarian cancer

Recruiting

Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.